The Industry Standard Disclosure Publication Service

Novel process for preparation of Methotrexate disodium salt

Disclosed anonymously

Database number 682004

Published in the February 2021 paper journal

Published digitally 23 December 2020 13:24 UT

Research Disclosure publication service

Research Disclosure is a unique international defensive publication service. For a minimal fee we publish inventions in our journal and online database. Once an invention has been published in Research Disclosure the concept is no longer novel and is established as prior art. This stops others from patenting the same invention anywhere in the world.

Under the Patent Cooperation Treaty, Research Disclosure's archive is named in the shortlist of PCT Minimum Documentation which patent examiners are required to consult, and is the only disclosure service to appear in this list. All submitted inventions are published in full in our paper journal. This is distributed globally and has an established legal precedent providing a publication date that can be reliably cited in courts worldwide.

The Research Disclosure journal is published on the 10th of every month. Disclosures can optionally be published online prior to being published in the next edition of the journal. To submit an article for publication simply email the file to publish@researchdisclosure.com.

Copyright statement

Questel Ireland Ltd gives consent for this disclosure to be printed or copied providing it is for individual use, for the internal use of patent examiners, specific clients, is not for resale and the copier pays the usual coping fees to the relevant Copyright Clearance Center. This consent does not extend to abstracting for the purpose of creating new collective works for resale. Document delivery services are expressly forbidden from scanning, printing or copying any Research Disclosure content for re-sale unless specifically licensed to do so by the publishers.

Novel process for preparation of Methotrexate disodium salt

Abstract:

A disclosure provides a novel process for preparation of methotrexate disodium salt.

Introduction:

Methotrexate is one of the oldest chemotherapy drugs. It has been used in the treatment of various forms of cancer; Methotrexate is also used in non-cancerous conditions such as psoriasis and rheumatoid arthritis. A number of marketed products contain the sodium salt of methotrexate.

Process for preparation of Methotrexate disodium salt.

The process comprising the step of 1) reacting 2, 4-diamino-6-hydroxymethylpteridine with thionyl chloride in presence of acetonitrile to obtain 2, 4-diamino-6-chloromethylpteridine hydrochloride, crystallized crude compound using mixture of acetic acid and formic acid to get 2, 4-diamino-6-chloro methylpteridine hydrochloride (acetic acid content ~ 10-35%); 2) condensation of obtained 2, 4-diamino-6-chloromethyl-pteridine hydrochloride with diethyl N (4-methyl aminobenzoyl) -L-glutamate in presence of KI and DMSO to obtain Methotrexate diethylester hydroiodide salt; 3) *insitu* hydrolysis of ester salt using NaOH in presence of THF and water followed by addition of IPA; obtained solid filtered; washed with acetone; recrystallized with THF; washed with acetone to obtain crude methotrexate disodium salt; 4) purification of methotrexate disodium salt by dissolving in water and ethanol (1:2) at 65°C, followed by cooling to room temperature, filtered and dried under vacuum to obtain pure methotrexate disodium salt.

RD 682004 Feb 2021 1/1 © Questel